Pulmonology

Arrowhead Pharmaceuticals Inc. announced that the company’s second-generation investigational medicine ARO-AAT was granted orphan drug designation by the FDA.

The chances of getting pregnant for current asthmatics who managed their symptoms with SABAs was 15% lower when compared to non-asthmatics.

A 20-year study of over 6000 European participants found reason to be concerned over the harm of cleaning chemicals.

When patients are given comprehensive education, have medications in hand, and have a follow-up appointment scheduled at discharge, they’re less likely to be readmitted to the hospital.

A new study finds tighter fuel standards for ships will have a major impact on public health globally.

The guidelines were created by Vanderbilt’s Asthma Steering Committee and implemented in May 2014.

Data published in The Orphanet Journal of Rare Diseases confirmed that currently-available enzyme replacement therapies are unable to reverse or stabilize the progression of Pompe disease.

The U.S. FDA approved tezacaftor/ivacaftor and ivacaftor (Symdeko) for the treatment of the underlying cause of cystic fibrosis in people ages 12 years and older who have 2 copies of the F508del mutation.

How a self-sustaining system of medical meetings draws experts and future leaders together.

The overall risk of asthma in childhood increases with maternal use of proton pump inhibitors and histamine-2 receptor antagonists.

Inhaled anticholinergic bronchodilator tiotropium as an add-on therapy has the potential to reduce exacerbations.

A newly developed Environmental Scoring System proves useful in disparate home-based asthma intervention programs.

This is the first gram-negative antibiotic approved in the US in over 15 years to treat HABP, VABP.

Alnylam has announced this afternoon that the U.S. FDA has accepted for filing its New Drug Application for patisiran, an investigational RNAi therapeutic targeting transthyretin for the treatment of hATTR amyloidosis.

The CDC attributes up to 21% of US asthma deaths to occupational exposures, and considers many potentially avoidable.

Results from a study recently published in the Orphanet Journal of Rare Diseases confirms the idea that tuberous sclerosis complex (TSC) can be diagnosed before seizure onset.

The first patient was enrolled in Mallinckrodt’s Phase 4 pilot study to further assess the efficacy of H.P. Acthar Gel (Repository Corticotropin Injection) in patients with pulmonary sarcoidosis.

This morning, Aradigm announced that it received a Complete Response Letter, denying its New Drug Application for Linhaliq.

Alnylam announced that its Marketing Authorisation Application for patisiran was accepted by the European Medicines Agency.

Faron Pharmaceuticals announced this morning that the U.S. FDA has approved the Investigational New Drug application for Traumakine (FP-1201-lyo) for the treatment of Acute Respiratory Distress Syndrome.

Children whose mothers had a higher intake of sugar sweetened beverages and total fructose had a 19% greater chance of developing asthma in mid-childhood.

Two doses of dexamethasone resulted in similar outcomes with better adherence than five days of prednisone in children with acute asthma.

Today, Eiger BioPharmaceuticals announced that results from the Phase 2 LIBERTY study demonstrated no improvement overall in its Phase 2 PAH treatment study, evaluating the effects of ubenimex.